Cluster immunotherapy - Inmunotek/ROXALL Medizin GmbH

Drug Profile

Cluster immunotherapy - Inmunotek/ROXALL Medizin GmbH

Alternative Names: Alxoid; Clustek; Cluster-allergoid - ROXALL Medizin GmbH; CLUSTOID; CLUSTOID® Wiesenlieschgras; CLUSTOID® Timothy; Glutaraldehyde polymerised allergen extract - ROXALL Medizin GmbH; Roxoid

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inmunotek
  • Developer Inmunotek; ROXALL Medizin GmbH
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis

Most Recent Events

  • 15 May 2014 ROXALL initiates enrolment in a phase II trial for Allergic rhinitis (In adults, In the elderly) in Germany (SC) (EudraCT2010-022083-12)
  • 01 Dec 2009 ROXALL completes a phase III trial in Allergic rhinitis (In adults, In the elderly) in Germany (SC) (NCT01012531)
  • 01 Oct 2008 Phase-III clinical trials in Allergic rhinitis (In adults, In the elderly) in Germany (SC) (NCT01012531)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top